Consensus Neurocrine Biosciences, Inc.

Equities

NBIX

US64125C1099

Delayed Nasdaq 01:16:00 24/07/2024 am IST 5-day change 1st Jan Change
145.43 USD +0.10% Intraday chart for Neurocrine Biosciences, Inc. -1.33% +10.42%

Evolution of the Average Target: Neurocrine Biosciences, Inc.

Evolution of the Target Price: Neurocrine Biosciences, Inc.

Changes in Analyst Recommendations: Neurocrine Biosciences, Inc.

a506c655ecb285ab1ed9de9606705.XF9BbTf1cc0U8FXbCClqYHEJLq5gPmy4ZO3oqAVLXGY.HzcwH1TMIv5tlDGqRG0GKQBxZM0FUTXZPMDekV0oG1IYchgbVLAHjGDBDA~d4051470194da2eda394325781179ec4
RBC Cuts Price Target on Neurocrine Biosciences to $136 From $141, Keeps Sector Perform Rating MT
ANALYST RECOMMENDATIONS : Alphabet, Nike, Nvidia, Tesla, Starbucks... Our Logo
Neurocrine Biosciences Insider Sold Shares Worth $1,401,864, According to a Recent SEC Filing MT
Neurocrine Biosciences Insider Sold Shares Worth $5,338,565, According to a Recent SEC Filing MT
UBS Raises Price Target on Neurocrine Biosciences to $193 From $174, Maintains Buy Rating MT
Neurocrine Biosciences Insider Sold Shares Worth $297,860, According to a Recent SEC Filing MT
Neurocrine Biosciences Insider Sold Shares Worth $4,138,436, According to a Recent SEC Filing MT
UBS Raises Price Target on Neurocrine Biosciences to $174 From $165, Maintains Buy Rating MT
Oppenheimer Adjusts Neurocrine Biosciences Price Target to $216 From $200, Maintains Outperform Rating MT
Wells Fargo Upgrades Neurocrine Biosciences to Overweight From Equalweight, Price Target is $170 MT
Morgan Stanley Lifts Price Target on Neurocrine Biosciences to $160 From $150, Sees Upside to Shares Ahead of Mid-Stage Readouts; Overweight Kept MT
JPMorgan Adjusts Price Target on Neurocrine Biosciences to $158 From $148, Maintains Overweight Rating MT
Oppenheimer Adjusts Neurocrine Biosciences Price Target to $200 From $170, Maintains Outperform Rating MT
UBS Adjusts Price Target on Neurocrine Biosciences to $159 From $128, Maintains Buy Rating MT
Deutsche Bank Raises Neurocrine Biosciences Price Target to $161 From $160, Maintains Buy Rating MT
Citigroup Trims Price Target on Neurocrine Biosciences to $140 From $141, Maintains Neutral Rating MT
Mizuho Securities Raises Price Target on Neurocrine Biosciences to $140 From $116, Maintains Neutral Rating MT
Wells Fargo Raises Price Target on Neurocrine Biosciences to $140 From $127, Maintains Equalweight Rating MT
Wedbush Adjusts Neurocrine Biosciences' Price Target to $147 From $141, Keeps Outperform Rating MT
Goldman Sachs Raises Price Target on Neurocrine Biosciences to $153 From $134, Maintains Buy Rating MT
Barclays Raises Neurocrine Biosciences' Price Target to $150 From $145, Maintains Overweight Rating MT
RBC Raises Price Target on Neurocrine Biosciences to $129 From $121, Keeps Sector Perform Rating MT
Stifel Adjusts Price Target on Neurocrine Biosciences to $144 From $141, Maintains Buy Rating MT
Wells Fargo Raises Price Target on Neurocrine Biosciences to $127 From $110, Keeps Equalweight Rating MT
Deutsche Bank Initiates Coverage on Neurocrine Biosciences With Buy Rating, $136 Price Target MT
More recommendations

Add to a list
Analyst Opinion 4m Revision of opinion Divergence of analysts' opinions Divergence of Target Price Ecart obj. / dr
+10.83%
-3.18%
+2.10%
+8.60%
+30.12%
+29.99%
+63.97%
+59.35%
+35.48%
+8.32%
Average +24.56%
Weighted average by Cap. +10.39%
See all sector consensus

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
145.28USD
Average target price
161.01USD
Spread / Average Target
+10.83%
High Price Target
216.00USD
Spread / Highest target
+48.68%
Low Price Target
111.00USD
Spread / Lowest Target
-23.60%

Analyst Consensus Detail

Consensus revision (last 18 months)

Analysts covering the company

UBS
Oppenheimer
Wells Fargo Securities
Morgan Stanley
JPMorgan Chase
Deutsche Bank Securities
Citigroup
Mizuho Securities
Wedbush
Goldman Sachs
Barclays
RBC Capital Markets
Stifel Nicolaus
Piper Sandler
Raymond James
Jefferies & Co.
HC Wainwright
Canaccord Genuity
BMO Capital
Baird
Guggenheim
Evercore ISI
SVB Securities LLC
Royal Bank of Canada
Cantor Fitzgerald
J.P. Morgan Chase
SVB Leerink
Credit Suisse
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
  1. Stock Market
  2. Equities
  3. NBIX Stock
  4. Consensus Neurocrine Biosciences, Inc.